XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited) - USD ($)
Total
Preferred Class A
Common Class B
Member Units
Preferred Class A
Member Units
Common Class B
Common Stock
Treasury Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Non-controlling Interests
Balance, beginning of period at Dec. 31, 2023 $ 2,580,605         $ 5,927   $ 155,615,962 $ 93,676 $ (148,240,859) $ (4,894,101)
Balance, beginning of period (in shares) at Dec. 31, 2023           124,659          
Balance, beginning of period (in shares) at Dec. 31, 2023 0                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Exercise of stock options and vesting of restricted stock (in shares)           17,414          
Exercise of stock options and vesting of restricted stock $ 0         $ 18   (18)      
Stock-based compensation 846,514             846,514      
Proceeds from stock offering, net of offering costs (in shares)           303,500          
Proceeds from stock offering, net of offering costs 5,029,422         $ 304   5,029,118      
Issuance of Pre-funded Warrants (in shares)           161,492          
Issuance of Pre-funded Warrants 108         $ 108          
Currency translation adjustment (13,651)               (13,651)    
Preferred dividends - non-controlling interest (75,004)                   (75,004)
Accretion on redeemable non-controlling interests preferred shares (161,466)                   (161,466)
Net loss (6,728,737)                 (6,714,438) (14,299)
Balance, end of period at Mar. 31, 2024 1,477,791         $ 6,357   161,491,576 80,025 (154,955,297) (5,144,870)
Balance, end of period (in shares) at Mar. 31, 2024           607,064          
Balance, beginning of period at Dec. 31, 2023 $ 2,580,605         $ 5,927   155,615,962 93,676 (148,240,859) (4,894,101)
Balance, beginning of period (in shares) at Dec. 31, 2023           124,659          
Balance, beginning of period (in shares) at Dec. 31, 2023 0                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Currency translation adjustment $ (19,530)                    
Net loss (12,327,595)                    
Balance, end of period at Sep. 30, 2024 3,004,987         $ 6,406   163,468,322 74,146 (160,543,887) 0
Balance, end of period (in shares) at Sep. 30, 2024           874,949          
Balance, beginning of period at Dec. 31, 2023 $ 2,580,605         $ 5,927   155,615,962 93,676 (148,240,859) (4,894,101)
Balance, beginning of period (in shares) at Dec. 31, 2023           124,659          
Balance, beginning of period (in shares) at Dec. 31, 2023 0                    
Preferred units, ending balance (in shares) at Dec. 31, 2024 0                    
Balance, end of period at Dec. 31, 2024 $ (1,289,647)         $ 6,408 $ 0 164,285,336 46,494 (165,599,076) (28,809)
Common unit, ending balance (in shares) at Dec. 31, 2024 0                    
Balance, end of period (in shares) at Dec. 31, 2024 904,949         903,269          
Balance, end of period (in shares) at Dec. 31, 2024 1,680           1,680        
Balance, beginning of period at Mar. 31, 2024 $ 1,477,791         $ 6,357   161,491,576 80,025 (154,955,297) (5,144,870)
Balance, beginning of period (in shares) at Mar. 31, 2024           607,064          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Exercise of stock options and vesting of restricted stock (in shares)           661          
Exercise of stock options and vesting of restricted stock 0         $ 1   (1)      
Stock-based compensation 481,800             481,800      
Exercise of Warrants /warrants issuance (in shares)           30,000          
Exercise of warrants 172,997         $ 30   172,967      
Issuance of Pre-funded Warrants (in shares)           14,998          
Issuance of Pre-funded Warrants 0         $ 15   (15)      
Currency translation adjustment (8,093)               (8,093)    
Preferred dividends - non-controlling interest (76,504)                   (76,504)
Accretion on redeemable non-controlling interests preferred shares (161,466)                   (161,466)
Net loss (3,949,015)                 (3,938,747) (10,268)
Balance, end of period at Jun. 30, 2024 $ (2,062,490)         $ 6,403   162,146,327 71,932 (158,894,044) (5,393,108)
Balance, end of period (in shares) at Jun. 30, 2024           652,723          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Common stock reverse split - rounding (in shares) 0         192,222          
Exercise of stock options and vesting of restricted stock (in shares) 0         4          
Stock-based compensation $ 601,075             601,075      
Exercise of Warrants /warrants issuance (in shares)           30,000          
Exercise of warrants 239,703         $ 3   239,700      
Currency translation adjustment 2,214               2,214    
Cancellation of non-controlling interests 5,874,328             481,220     5,393,108
Net loss (1,649,843)                 (1,649,843)  
Balance, end of period at Sep. 30, 2024 3,004,987         $ 6,406   163,468,322 74,146 (160,543,887) 0
Balance, end of period (in shares) at Sep. 30, 2024           874,949          
Balance, beginning of period at Dec. 31, 2024 $ (1,289,647)         $ 6,408 $ 0 164,285,336 46,494 (165,599,076) (28,809)
Balance, beginning of period (in shares) at Dec. 31, 2024 904,949         903,269          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Stock-based compensation $ 554,659             554,659      
Proceeds from direct offering, net of offering costs (in shares)           213,428          
Proceeds from direct offering, net of offering costs 564,868         $ 21   564,847      
Exercise of Warrants /warrants issuance (in shares)           431,652          
Exercise of warrants 854,096         $ 43   854,053      
Conversion of Convertible Notes, net of offering costs (in Shares)           1,568,019          
Conversion of convertible notes, net of offering costs 2,952,583         $ 157   2,952,426      
Currency translation adjustment 236               236    
Net loss (6,878,601)                 (6,873,003) (5,598)
Preferred units, ending balance (in shares) at Mar. 31, 2025       0              
Balance, end of period at Mar. 31, 2025 $ (3,241,806)     $ 0 $ 0 $ 6,629 $ 0 169,211,321 46,730 (172,472,079) (34,407)
Common unit, ending balance (in shares) at Mar. 31, 2025         0            
Balance, end of period (in shares) at Mar. 31, 2025           3,116,368          
Balance, end of period (in shares) at Mar. 31, 2025             1,680        
Preferred units, beginning balance (in shares) at Dec. 31, 2024 0                    
Balance, beginning of period at Dec. 31, 2024 $ (1,289,647)         $ 6,408 $ 0 164,285,336 46,494 (165,599,076) (28,809)
Common unit, beginning balance (in shares) at Dec. 31, 2024 0                    
Balance, beginning of period (in shares) at Dec. 31, 2024 904,949         903,269          
Balance, beginning of period (in shares) at Dec. 31, 2024 1,680           1,680        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Common stock reverse split - rounding (in shares)           192,222          
Currency translation adjustment $ (6,006)                    
Net loss $ (25,241,278)                    
Preferred units, ending balance (in shares) at Sep. 30, 2025 4,900,000     4,900,000              
Balance, end of period at Sep. 30, 2025 $ (1,918,477)     $ 166,698 $ 150,000 $ 8,565 $ 0 188,584,935 40,488 (190,358,139) (511,024)
Common unit, ending balance (in shares) at Sep. 30, 2025 150,000       150,000            
Balance, end of period (in shares) at Sep. 30, 2025 22,482,750         22,482,750          
Balance, end of period (in shares) at Sep. 30, 2025 1,680           1,680        
Preferred units, beginning balance (in shares) at Mar. 31, 2025       0              
Balance, beginning of period at Mar. 31, 2025 $ (3,241,806)     $ 0 $ 0 $ 6,629 $ 0 169,211,321 46,730 (172,472,079) (34,407)
Common unit, beginning balance (in shares) at Mar. 31, 2025         0            
Balance, beginning of period (in shares) at Mar. 31, 2025           3,116,368          
Balance, beginning of period (in shares) at Mar. 31, 2025             1,680        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Stock-based compensation 14,022             14,022      
Exercise of Warrants /warrants issuance (in shares)           1,651,643          
Exercise of warrants 1,221,249         $ 165   1,221,084      
Warrants issuance 8,194,000             8,194,000      
Proceeds from stock offering, net of offering costs (in shares)       4,900,000 100,000            
Proceeds from stock offering, net of offering costs   $ 774,976 $ 100,000 $ 774,976 $ 100,000            
Conversion of Convertible Notes, net of offering costs (in Shares)           6,153,330          
Conversion of convertible notes, net of offering costs 3,670,630         $ 609   3,670,020      
Currency translation adjustment 7,151               7,151    
Net loss (13,568,462)                 (13,378,800) (189,662)
Preferred units, ending balance (in shares) at Jun. 30, 2025       4,900,000              
Balance, end of period at Jun. 30, 2025 (2,828,239)     $ 774,976 $ 100,000 $ 7,404 $ 0 182,310,448 53,881 (185,850,879) (224,069)
Common unit, ending balance (in shares) at Jun. 30, 2025         100,000            
Balance, end of period (in shares) at Jun. 30, 2025           10,921,341          
Balance, end of period (in shares) at Jun. 30, 2025             1,680        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Stock-based compensation 245,624             245,624      
Exercise of Warrants /warrants issuance (in shares)           50,000          
Exercise of warrants 8,555         $ 5   8,550      
Proceeds from stock offering, net of offering costs (in shares)         50,000 3,798,874          
Proceeds from stock offering, net of offering costs 3,059,162 $ (608,278) $ 50,000 $ (608,278) $ 50,000 $ 380   3,058,782      
Conversion of Convertible Notes, net of offering costs (in Shares)           6,204,740          
Conversion of convertible notes, net of offering costs 1,076,463         $ 625   1,075,838      
Issuance of Pre-funded Warrants (in shares)           1,507,795          
Issuance of Pre-funded Warrants 1,885,844         $ 151   1,885,693      
Currency translation adjustment (13,393)               (13,393)    
Net loss $ (4,794,215)                 (4,507,260) (286,955)
Preferred units, ending balance (in shares) at Sep. 30, 2025 4,900,000     4,900,000              
Balance, end of period at Sep. 30, 2025 $ (1,918,477)     $ 166,698 $ 150,000 $ 8,565 $ 0 $ 188,584,935 $ 40,488 $ (190,358,139) $ (511,024)
Common unit, ending balance (in shares) at Sep. 30, 2025 150,000       150,000            
Balance, end of period (in shares) at Sep. 30, 2025 22,482,750         22,482,750          
Balance, end of period (in shares) at Sep. 30, 2025 1,680           1,680